Population
A nationwide retrospective multicentric review of all pediatric cases with OMT treated between January 2007 and December 2016 was conducted in France. Eligible patients were females under 18 years of age at diagnosis who underwent surgery for histologically proven OMT. Cases were extracted by analyzing local and national databases of theSociété Française de lutte contre les Cancers et les leucémies de l’Enfant (SFCE), the “Société Française de Chirurgie pédiatrique ” (SFCP), the FrePSO (French Pediatric Surgeons Oncology) group, the “Comité de Coordination de Pathologie Pédiatrique et Périnatale ” (CCOPPP) and the FRACTURE (Groupe Français des tumeurs rares ). Data on clinical features, imaging and laboratory studies, surgical reports, pathological diagnoses and outcomes were collected. Information on the management of second events and long-term morbidity was also retrieved through the reports of the postoperative consultations where abdominal ultrasound was carried out. In the absence of consensus in the literature (17-19), the schedule of this follow-up (FU) program differed from one center to another.
We defined persistent first complete remission (CR1) as patients who did not experience any second event after initial surgery during the FU and second (CR2) and third (CR3) complete remission as patients in remission after one or two second events. A second event was considered when a new ovarian mass, suggesting a new tumor, occurred in the same or in the contralateral ovary after initial surgery. Pathological analysis should be documented when a second surgery is carried out or highly suggestive on imaging and biological work-up if the management is limited to surveillance.